Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

Gene expression testing helps determine chemotherapy needs for hormone receptor-positive breast cancer, optimizing treatment ...

Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

Why do medications that are supposed to help patients with chronic inflammatory diseases sometimes lead to blood clots?

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is an emerging cancer therapeutic that just recently gained Food and Drug Administration approval for treatment of estrogen receptor ...

We utilized RevMan5.3 software to perform the meta-analysis. Conclusions: Our meta-analysis demonstrates that the addition of CDK4/6 inhibitors to endocrine therapy can result in improved PFS and OS ...

All patients received an aromatase inhibitor and a CDK4/6 inhibitor—either Lilly’s Verzenio, Novartis’ Kisqali or Pfizer’s Ibrance—as their first-line treatment. Physicians monitored ...

Camizestrant combined with CDK4/6 inhibitors improved progression-free survival in HR+/HER2- advanced breast cancer with ESR1 mutations in the SERENA-6 trial. In the phase 3 SERENA-6 trial ...